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LESS IS MORE
ORIGINAL INVESTIGATION
Potentially Inappropriate Medications Defined
by STOPP Criteria and the Risk of Adverse Drug
Events in Older Hospitalized Patients
Hilary Hamilton, MB, MRCPI; Paul Gallagher, PhD, MRCPI; Cristin Ryan, PhD, MPSI;
Stephen Byrne, PhD, MPSI; Denis O’Mahony, MD, FRCPI
Background: Previous studies have not demonstrated
a consistent association between potentially inappropri-
atemedicines (PIMs) in older patients as defined by Beers
criteria and avoidable adverse drug events (ADEs). This
study aimed to assess whether PIMs defined by new
STOPP (Screening Tool of Older Persons’ potentially in-
appropriate Prescriptions) criteria are significantly as-
sociated with ADEs in older people with acute illness.
Methods:Weprospectively studied 600 consecutive pa-
tients 65 years or older who were admitted with acute
illness to a university teaching hospital over a 4-month
interval. Potentially inappropriate medicines were de-
fined by both Beers and STOPP criteria. Adverse drug
events were defined by World Health Organization–
Uppsala Monitoring Centre criteria and verified by a lo-
cal expert consensus panel, which also assessed whether
ADEs were causal or contributory to current hospital-
ization. Hallas criteria definedADE avoidability.We com-
pared the proportions of patients takingBeers criteria PIMs
and STOPP criteria PIMs with avoidable ADEs that were
causal or contributory to admission.
Results: A total of 329 ADEswere detected in 158 of 600
patients (26.3%); 219 of 329 ADEs (66.6%) were consid-
eredcausalor contributory toadmission.Of the219ADEs,
151(68.9%)consideredcausalorcontributorytoadmission
wereavoidableorpotentially avoidable.After adjusting for
age, sex, comorbidity, dementia, baseline activities of daily
living function, andnumberofmedications, the likelihood
of a serious avoidable ADE increased significantly when
STOPPPIMswere prescribed (odds ratio, 1.847; 95%con-
fidence interval [CI], 1.506-2.264; P .001); prescription
ofBeerscriteriaPIMsdidnotsignificantly increaseADErisk
(odds ratio, 1.276; 95% CI, 0.945-1.722; P=.11).
Conclusion:STOPPcriteriaPIMs,unlikeBeerscriteriaPIMs,
are significantly associated with avoidable ADEs in older
people that cause or contribute to urgent hospitalization.
Arch Intern Med. 2011;171(11):1013-1019
I NAPPROPRIATE MEDICATION USE IShighly prevalent among olderpeople, particularly those pre-senting to a hospital with acuteillness.1,2 Certain drugs are con-
sidered inappropriate or potentially inap-
propriate in old age because of the higher
risk of intolerance related to adverse phar-
macodynamics or pharmacokinetics or
drug-disease interactions. These observa-
tions have formed the basis for various sets
of criteria for potentially inappropriate
medication in older people, the best known
of which is Beers criteria.3-5 Beers criteria
were developed in the United States and
first published in 19913 and subse-
quently revised in 19976 and most re-
cently in 2003.5
The 2003 iteration of Beers criteria con-
sists of 2 lists of drugs to be avoided in
older people (1) independent of diagno-
sis and (2) considering diagnosis. Beers cri-
teria explicitly caution prescribers to avoid
certain drugs (independent of diagnosis)
in all older people and to avoid other drugs
in some older people with certain medi-
cal conditions because of poor risk to ben-
efit ratio and consequently increased risk
of adverse drug events (ADEs). Onewould
therefore reasonably expect a significant
association between potentially inappro-
priate medications (PIMs) and ADEs.
However, 2 recent large-scale retrospec-
tive studies that specifically examined the
association between Beers criteria PIMs
and the incidence of ADEs1,7 found no sta-
tistically significant association. An Ital-
ian study of 1756 older patients admitted
to a geriatric unit found that 4.4% of hos-
pitalizations were related to ADEs that
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were definitely or possibly avoidable.8 Of those patients
whose hospitalization resulted from potentially avoid-
able ADEs, one-fifth (1% of all admissions) had re-
ceived an inappropriate medication or a drug not indi-
cated for the diagnosed disease. A US-based study using
the 2003 iteration of Beers criteria showed no signifi-
cant causal link between Beers criteria PIMs and ADEs9
identified from emergency department visits by very large
numbers of older patients (n=177 504).
In contrast to these negative study findings, other stud-
ies have found a significant association between PIMs and
ADEs. A study of 550 older people attending an out-
patient clinic in Taiwan found that those taking Beers cri-
teria PIMs had a relative risk of adverse drug reactions
more than 15 times that of persons who were not taking
Beers criteria PIMs.10 A smaller-scale Brazilian study of
186 older people11 found that prescription of a Beers cri-
teria PIM increased the risk of an adverse drug reaction
by a factor of 2.3. A recent study of Medicare beneficia-
ries found that the risk of ADEs was doubled by inap-
propriate medication use,12 although the definition of in-
appropriatemedicationwas not confined to Beers criteria
PIMs.
Most studies to date examining the association be-
tween PIMs and ADEs have also been limited by their
retrospective design and restricted use of the limited “in-
dependent of diagnosis” subset of Beers criteria, whose
transferability had been questioned because of the in-
clusion of many medications that are not available out-
side the United States. The lack of a reproducible, sta-
tistically significant association between Beers criteria
PIMs and ADEs in these studies is also counterintuitive.
If the purpose of defining criteria for PIMs is to high-
light the inherent increased risk of ADEs, one would ex-
pect a significant and consistent association betweenBeers
criteria PIMs and ADEs. The lack of a consistent asso-
ciation suggests that Beers criteria may be inadequate in
their inclusion of drugs linked to the commonADEs seen
in older people. Because of these perceived deficiencies
of Beers criteria, our research group recently devised and
validated a new set of PIM criteria in older people, called
STOPP (Screening Tool of Older Persons’ potentially in-
appropriate Prescriptions).13,14 STOPP criteria are based
on commonly encountered PIMs and are listed accord-
ing to physiological systems, as is the casewithmost drug
formularies. They include 65 instances of more com-
mon and more important PIMs that predispose to ADEs
in older people. The inter-rater reliability of STOPP has
been established, as well as its performance in lan-
guages other than English, in a recent study involving 6
comparable teaching hospital centers in Europe.15 The
essential differences between STOPP criteria and Beers
criteria are as follows:
1. STOPP criteria are organized according to physi-
ological systems, whereas Beers criteria are not.
2. STOPP criteria deal with drugs that are currently
in widespread use; Beers criteria include several drugs
that are no longer available in most European countries,
eg, trimethobenzamide, carisoprodol, clidinium-
chlordiazepoxide, guanadrel, oxaprozin, and ethacry-
nic acid.
3. STOPP criteria place special emphasis on poten-
tial adverse drug-drug interactions and duplicate drug
class prescription, whereas Beers criteria do not.
4. STOPP criteria contain several common instances
of potentially inappropriate prescribing that are notmen-
tioned in Beers criteria.13,14
STOPP criteria and Beers criteria have several areas
of overlap. Both sets of criteria emphasize the higher risk
of adverse drug reactions and events in older people with
use of long-acting benzodiazepines, tricyclic antidepres-
sants, anticholinergic drugs, and non–cyclooxygenase
2–selective nonsteroidal anti-inflammatory drugs. Both
sets of criteria also focus on several common potential
adverse drug-disease interactions in older people.
The incidence of STOPP-listed PIMs in older people
presenting to a hospital with acute illness is approxi-
mately 35%.2 A recent study of acutely ill older patients
showed that ADEs resulting from STOPP criteria PIMs
were almost twice as likely to be causal or contributory
to hospitalization as ADEs resulting from Beers 2003 cri-
teria.2 However, the identification of ADEs in that study
was based on trained clinical judgment as opposed to strict
causality and avoidability criteria.
The aims of the present studywere to (1) compare the
prevalence of ADEs associated with the PIMs listed by
STOPP criteria and Beers criteria, (2) compare STOPP
criteria and Beers criteria in terms of their associationwith
avoidable ADEs that cause or contribute to urgent hos-
pital admission, and (3) determine whether ADEs iden-
tified by an expert consensus panel are significantly and
independently associated with PIMs defined by STOPP
criteria and Beers criteria.
METHODS
Ethical approval was sought and obtained by the local re-
search ethics committee. We collected data prospectively on
600 consecutive unselected patients 65 years or olderwith acute
illness at the point of hospital admission. Patients were admit-
ted to a variety of medical and surgical services throughout the
hospital. However, all data were collected within the first 24
hours of admission in the emergency department in more than
90% of cases, before patients were transferred to the various
appropriate specialist departments.We recorded details of cur-
rent and previous medical diagnoses, comorbidity burden
(Charlson Comorbidity Index score), presence or absence of
chronic cognitive impairment, current regular prescriptionmedi-
cines, current blood pressure, hematological and biochemical
profiles, electrocardiograph results, and history of drug al-
lergy or intolerance.Nonprescription (over-the-counter [OTC])
medication intake was not recorded because OTC drugs are
tightly controlled in Ireland comparedwith other countries, and
consequently, OTC drug use in Ireland is not considered an
important cause of ADEs (except in cases of overdose). Activi-
ties of daily living (ADL) function wasmeasured using the Bar-
thel Index score.16 Details were obtained from current hospi-
tal records aswell as frompatient and caregiver interviews.When
necessary, patients’ primary care physicians and community
pharmacists were contacted for essential details.
DetectionofPIMswasbasedonpatients’medicationsatthepoint
of hospital admission, prior to anymodificationsmadeby the ad-
mitting team. STOPPcriteria andBeers criteriawere thenapplied
to the combined patient clinical profile and juxtaposed medica-
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tion list, and instances of PIMswere recorded, ie, PIMs that were
related topreadmissionmedicationsonlyanddidnot includepre-
scribedmedicationsduring the indexhospital admission.Adverse
drug events were only included if they occurred after PIM expo-
sure andbefore hospitalmanagement began, ie, ADEspertaining
onlytopreadmissionprescriptionmedicationswere identifiedand
not those occurring during the hospitalization. An ADE was de-
fined as any noxious, unintended, andundesired effect of a drug,
excluding therapeutic failures, intentional or accidental poison-
ing,anddrugabuse.17AllsuspectedADEswereindividuallyanalyzed
byapanelof4experts ingeriatricpharmacotherapy(2physicians
[D.O’M.andP.G.]and2pharmacists[S.B.andC.R.])affiliatedwith
theSchoolsofMedicineandPharmacyatUniversityCollegeCork,
Cork, Ireland. World Health Organization–Uppsala Monitoring
Centre (WHO-UMC) criteria18 were used to define ADEs, and a
consensus agreement of at least 3 of the 4 expertswas used to de-
finewhetherADEswere (1)causalor contributory tohospital ad-
mission or (2) incidental findings detected and not related to the
causeof admission.Adversedrug event avoidabilitywas assessed
usingHallas criteria.19 The panel convenedweekly in a group fo-
rum,discussedeachcase indetail, andchecked reference sources
suchas theBritishNationalFormularyandreputablepharmacol-
ogy texts. Individual panel members voted on whether the ADE
wascausalorcontributory toadmissionandwhether theADEmet
individual Hallas criteria. The panelists were not asked to apply
STOPPorBeerscriteriatotheclinicalandprescriptioninformation—
onlytocommentonthepresenceofADEsandwhethertheyjudged
theADEas being (1) causal or contributory to admission and (2)
avoidable (using Hallas criteria). All of the criteria, both consid-
eringdiagnosis anddependentondiagnosis, in the latest iteration
ofBeerscriteria5wereapplied to thepreadmissionclinicalandpre-
scription data. Variableswere dichotomously coded, ie, a patient
had at least 1 potentially inappropriate prescription according to
all of Beers criteria or had no inappropriate prescriptions.
The proportions of definitely avoidable or potentially avoid-
able ADEs detected by STOPP criteria and Beers criteria were
calculated to determine any significant difference in the abil-
ity of the 2 sets of PIM criteria to detect (predict) clinically rel-
evant ADEs, as determined by expert consensus agreement.
These proportions were compared using the 2 test. We used
multiple logistic regression analysis to determinewhether ADEs
were independently associated with PIMs as defined by STOPP
criteria and Beers criteria. Only 1 logistic regressionmodel was
constructed to examine the influence of age, sex, number of
medications, burden of comorbidity, cognitive impairment, pres-
ence of 1 or more STOPP criteria PIMs, and presence of 1 or
more Beers criteria PIMs on the presence of ADEs at the time
of admission. SPSS version 15 (SPSS Inc, Chicago, Illinois) was
used to process all statistical data.
RESULTS
Details of age, sex, place of residence, functional status,
recent falls, and recent hospitalization are presented in
Table 1. The median age of the entire group of 600 pa-
tientswas 77 years (interquartile range [IQR], 72-83 years)
and 241 patients (40.2%) were male. Of the patients,
48.0% had a Charlson Comorbidity Index score of 2 or
higher, and 19.5% of patients had a history of chronic
cognitive impairment. A total of 4523 medications were
prescribed for the 600 patients (median number, 7 per
patient [range, 1-27; IQR, 5-10]); 34.0% of patients were
prescribed 5 or fewer daily regular prescription drugs,
46.0% were prescribed 6 to 10 daily drugs, and 20.0%
were prescribed more than 10 daily medications. Ac-
cording to STOPP criteria, 610 PIMs were identified in
337 patients (56.2% of all patients). With Beers criteria,
235 PIMs were identified in 173 patients (28.8% of all
patients).
Table 1. Baseline Characteristics of Patients With and Without ADEs on Admission to Hospital
Variable
No. (%)
Test Statistic For
Difference Between Groups P Value
Patients With
at Least 1 ADE
Patients With
No ADE
Age, y
Median (IQR) 79 (73-84) 77 (72-83) Mann-Whitney=31545.00 .07
65-74 48 (30.4) 159 (36)
75-84 77 (48.7) 195 (44.1) 22=1.658 .44
85 33 (20.9) 88 (19.9)
Sex 21=4.698 .03
Female 106 (67.1) 253 (57.2)
Male 52 (32.9) 189 (42.8)
Place of residence 22=21.680 .001
Home 125 (79.1) 408 (92.3)
Nursing home 25 (15.8) 29 (6.6)
Sheltered accommodation 8 (5.1) 5 (1.1)
Functional level 2=19.677 .001
Independent in ADLs 86 (54.4) 325 (73.5)
Needs help with 1 ADL 72 (45.6) 117 (26.5)
Falls 21=22.560 .001
1 Fall in 3 mo before
admission
125 (79.1) 256 (57.9)
No falls in 3 mo before
admission
33 (20.9) 186 (42.1)
Hospitalization 28=6.104 .64
1 In previous year 71 (44.9) 186 (42.1)
None in previous year 87 (55.1) 256 (57.9)
Abbreviation: ADEs, adverse drug events; ADLs, activities of daily living; IQR, interquartile range.
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The breakdown of the study data is illustrated in the
Figure. A total of 329 ADEs were identified in 158 of the
600 patients (26.3%). Of the 329 ADEs, 36 (10.9%) were
judged by consensus agreement to have been the princi-
pal cause of the index hospitalization. These 36 ADEs oc-
curred in 36 patients, ie, 6.0% of the total patient popula-
tion. The consensus panel judged 183 of the 329 ADEs
(55.6%) to have been a clinically significant contributory
factor to the indexhospital admission, asdistinct frombeing
theundisputedprimecause.Thus,219of329ADEs(66.6%)
were either causal or significantly contributory to admis-
sion in the 158patients (26.3%) judgedby consensus panel
agreement tohave experienced a clinically significantADE.
Of the 329ADEs identified by expert panel consensus, 170
(51.7%) involved STOPP criteria PIMs compared with 67
ADEs (20.4%) related to Beers criteria PIMs (P .01), ie,
clinically significantADEswere listed inSTOPPcriteria2.54
times more often than in Beers criteria. Table 2 gives the
most commonly prescribed PIMs as per STOPP criteria;
Table 3 gives the equivalent list as per Beers criteria.
Of the 329ADEs, 235 (71.4%)were classified as avoid-
ableorpotentiallyavoidableaccording toHallascriteria.Of
these 235 avoidable or potentially avoidable ADEs, 159
(67.7%) involvedSTOPPcriteriaPIMs;67avoidableorpo-
tentiallyavoidableADEs(28.5%)involvedBeerscriteriaPIMs,
with a significant difference ofP .001.Of the total of 329
ADEs, 219 were judged causal or contributory to hospital
admission,andofthese219ADEs,108weredefinitelyavoid-
ableand43werepossiblyavoidable, ie,151ADEsthatwere
causal or contributory tohospital admissionwere simulta-
neously definitely or possibly avoidable according to Hal-
lascriteria.Ofthese151definitelyorpossiblyavoidableADEs,
94 (62.2%) were listed in STOPP criteria. By comparison,
34of the151definitelyorpossiblyavoidableADEsthatwere
causal or contributory to admission (22.5%)were listed in
Beerscriteria,withasignificantdifferenceofP.001,ie,defi-
nitely or possibly avoidableADEs relevant to the index ad-
mission were listed 2.76 times more frequently in STOPP
criteria than inBeers criteria (Table4).Table5 gives the
Patient admissions600
ADEs causal or contributory to 
admission and avoidable listed 
in STOPP criteria (62.2% of 
causal and avoidable ADEs)
94 ADEs causal or contributory to 
admission and avoidable listed 
in Beers criteria (22.5% of 
causal and avoidable ADEs)
34
ADEs in 158 patients329
WHO definition 
of ADE and expert 
panel consensus 
ADEs causal or contributory
to immediate admission  
219
WHO-UMC ADE
causality criteria
and expert panel
consensus
ADEs causal or contributory
to immediate admission and
definitely or possibly avoidable
151Hallas criteria
for ADE
avoidability
Figure. Flow chart showing how 600 consecutively hospitalized older
patients were classified according to the ADEs identified. The chart shows
whether ADEs were causal or contributory to admission (WHO-UMC criteria
plus expert panel consensus) and whether ADEs were avoidable or possibly
avoidable (Hallas criteria). ADEs indicates adverse drug events;
STOPP, Screening Tool of Older Persons’ potentially inappropriate
Prescriptions; WHO, World Health Organization; and WHO-UMC, World
Health Organization–Uppsala Monitoring Centre.
Table 2. Most Commonly Prescribed Potentially
Inappropriate Medications (PIMs) as per STOPP Criteriaa
STOPP Criteria PIMs No.b
Proton pump inhibitors for uncomplicated peptic ulcer
disease at full therapeutic dosage for 8 wk
128
Aspirin with no history of coronary, cerebral, or peripheral
vascular symptoms or occlusive arterial events
66
Benzodiazepines in patients who have had 1 fall in the past
3 mo
56
Duplicate drug class prescriptions 56
Long-term (1 mo), long-acting benzodiazepines or
benzodiazepines with long-acting metabolites
48
Loop diuretic as first-line monotherapy for hypertension 24
Long-term use of nonsteroidal anti-inflammatory drugs
(3 mo) for relief of mild joint pain in osteoarthritis
19
Long-term opiates in those with recurrent falls (1 fall in
past 3 mo)
18
Neuroleptic drugs in those with recurrent falls (1 fall in
past 3 mo)
16
Long-term opiates in those with recurrent falls (1 fall in
past 3 mo)
14
Abbreviation: STOPP, Screening Tool of Older Persons’ potentially
inappropriate Prescriptions.
aA total of 610 STOPP criteria PIMs were prescribed to the 600 patients
studied.
bThe number of PIM instances.
Table 3. Most Commonly Prescribed Potentially
Inappropriate Medications (PIMs) as per Beers Criteriaa
Beers Criteria PIMs No.b
Short- to intermediate-acting benzodiazepines and tricyclic
antidepressants (imipramine hydrochloride, doxepin
hydrochloride, and amitriptyline hydrochloride) in
patients with a history of syncope or falls
35
Long-term benzodiazepines or sympatholytics
(methyldopa, reserpine, and guanethidine) in patients
with depression
26
Long-acting benzodiazepines (chlordiazepoxide,
chlordiazepoxide-amitriptyline, diazepam, quazepam,
halazepam, and chlorazepate)
25
Doxazosin mesylate 24
Flurazepam hydrochloride 18
Prescription of amitriptyline,
chlordiazepoxide-amitriptyline and
perphenazine-amitriptyline
18
Short-acting benzodiazepines: doses greater than
lorazepam, 3 mg; oxazepam, 60 mg; alprazolam, 2 mg;
temazepam, 15 mg; triazolam 0.25mg
13
Prescription of calcium channel blockers, anticholinergics,
tricyclic antidepressants (imipramine, doxepin, and
amitriptyline) in patients with constipation
11
Prescription of aspirin, nonsteroidal anti-inflammatories,
dipyridamole, clopidogrel or ticlopidine hydrochloride in
patients with blood-clotting disorders or receiving
anticoagulant therapy
10
Amiodarone 8
aA total of 235 Beers criteria PIMs were prescribed among the 600
patients studied.
bThe number of PIM instances.
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most common ADEs that were judged causal or contribu-
tory to the index hospitalization and simultaneously defi-
nitely or possibly avoidable.
After adjusting for age, sex, comorbidity, chronic cog-
nitive impairment, baseline ADL function, and number
of medications, the likelihood of an ADE increased by
84.7% with each STOPP criteria PIM (odds ratio, 1.847;
95% confidence interval, 1.506-2.264; P .001) (eTable;
http://www.archinternmed.com). In contrast, prescrip-
tion of a Beers criteria PIM did not significantly increase
the likelihood of an ADE (odds ratio, 1.276; 95% confi-
dence interval, 0.945-1.722; P=.11).
COMMENT
The principal findings of this study include the
following:
1. Adverse drug events in acutely ill older patients pre-
senting to a hospital involved STOPP criteria PIMs 2.54
times more frequently than Beers criteria PIMs.
2. Avoidable or potentially avoidable ADEs identi-
fied in these patients involved STOPP criteria PIMs in
67.7% of instances, compared with Beers criteria PIMs
in 28.5% of instances.
3. Adverse drug events that were definitely or possi-
bly avoidable and simultaneously causal or contribu-
tory to urgent hospitalization were listed in STOPP cri-
teria almost 2.8 times more frequently than in Beers
criteria—a significant difference.
4. After adjusting for age, sex, ADL functional status,
comorbidity, cognitive impairment, and number ofmedi-
cations, the likelihood of patients experiencing an ADE
was almost 85%higher if theywere prescribed STOPP cri-
teria PIMs than if they were not prescribed STOPP crite-
ria PIMs—a significant difference. In contrast, beingmedi-
catedwith Beers criteria PIMsdid not significantly increase
patients’ odds of experiencing an ADE.
The present study results indicate that STOPP crite-
ria are more sensitive to PIMs that result in ADEs than
Beers criteria and are therefore more clinically relevant.
To be clinically relevant, PIMs included in a prioritized
list to assist the prescriber ormedication reviewer inmini-
mizing drug-related adversity should contain a high pro-
portion of drugs that actually cause or predict clinically
significant ADEs. The data from the studies by Onder et
al1 (2005) and Laroche et al7 (2007) indicate that Beers
criteria were insufficient in this regard and are therefore
of questionable relevance to the prevention of ADEs in
Table 4. Comparison of STOPP Criteria and Beers Criteria in Terms of Total ADEs Identified and Total ADEs Deemed Avoidable
(Hallas Criteria)a
STOPP Criteria Beers Criteria
No. of ADEs of the 329 ADEs identified by expert consensus panel and simultaneously listed in PIM criteria 170b 67
No. of consensus panel–identified ADEs deemed avoidable or potentially avoidable (n=235) and simultaneously
identified by PIM criteria
159b 67
No. of consensus panel–identified ADEs deemed causal or contributory to index hospital admission and
simultaneously avoidable or potentially avoidable (n=151) identified by PIM criteria
94b 34
Abbreviations: ADEs, adverse drug events; PIM, potentially inappropriate medicine; STOPP, Screening Tool of Older Persons’ potentially inappropriate
Prescriptions.
aThe expert panel identified 329 ADEs in 158 of the 600 patients (26.3%), independent of STOPP criteria and Beers criteria. Of the 329 ADEs, 235 were judged
to be avoidable or potentially avoidable.
bSignificant difference (2 test, P .001).
Table 5. Most Common ADEs That Were Classified as Causal or Contributory to Admission and Possibly or Definitely Avoidable
as per Hallas Criteria
ADE No. (%)
No. (%)
Attributed to
STOPP Criteria
PIMs
Attributed to
Beers Criteria
PIMs
ADEs Appearing
Both in STOPP
and Beers Criteria
Fall(s) while receiving benzodiazepines 24 (15.9) 24 (100) 22 (91.7) 22 (91.7)
Symptomatic orthostasis while receiving antihypertensives 17 (11.3) 15 (88.2) 1 (5.9) 1 (5.9)
Falls while receiving opiates 10 (6.6) 10 (100) 0 0
Hyponatremia while receiving diuretics 10 (6.6) 0 0 0
Constipation while receiving opiates 6 (4.0) 6 (100) 0 0
Falls while receiving sedative hypnotics 6 (4.0) 0 0 0
Acute kidney injury while receiving diuretics 6 (4.0) 3 (50) 0 0
Symptomatic orthostasis while receiving diuretics 5 (3.3) 5 (100) 0 0
Falls on neuroleptics 5 (3.3) 5 (100) 1 (20) 0
NSAID-related gastritis/peptic ulcer disease 4 (2.6) 3 (75) 1 (25) 1 (25)
Bradycardia while receiving -blockers 4 (2.6) 0 0 0
Abbreviations: ADEs, adverse drug events; NSAID, nonsteroidal anti-inflammatory drug; PIMs, potentially inappropriate medicines; STOPP, Screening Tool of
Older Persons’ potentially inappropriate Prescriptions.
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older people. Particular strengths of the present study in-
clude its prospective design and the fact that all relevant
clinical and laboratory data were collected contempora-
neously, enabling the full deployment of Beers criteria
both independent of and considering diagnosis (unlike
most studies to date). This study also examined ADE
avoidability using the widely cited Hallas criteria to de-
termine the proportion of ADEs that could reasonably
have been predicted and prevented, as distinct from those
ADEs resulting from unpredictable idiosyncratic medi-
cation reactions, or ADEs arising from medications that
are clinically appropriate (eg, bleeding with anticoagu-
lants). The scrutiny of all possible or suspected ADEs by
a panel of experts in geriatric pharmacotherapy is likely
to have maximized the detection of potential ADEs, un-
like most published studies to date, which are retrospec-
tive and either do not define ADEs at all or in some in-
stances rely on patients’ self-reports of ADEs.12 Using a
more rigorous approach, we show that the PIMs listed
in STOPP criteria are significantly more likely to be as-
sociated with carefully identified ADEs than were PIMs
listed in Beers criteria. Thus, STOPP criteria as a pro-
cessmeasure of prescribing appropriateness can be clearly
linked to an important health outcome, ie, ADEs. In con-
trast, Beers criteria PIMs in the present study were not
significantly associated with a significantly higher risk
of ADEs.We believe that this finding strengthens the ar-
gument for the use of STOPP criteria in everyday clini-
cal practice as a means of reducing the risk of ADEs in
older patients.
Previously published data from our group show that
the prevalence of STOPP criteria PIMs in older people is
appreciable in various clinical settings, ie, 21.4% in pri-
mary care,20 34.5% in secondary (hospital) care,2 and
73.1% in nursing home care.21 Given the current data
showing that PIMs are clinically significant in relation
to ADEs, application of the STOPP criteria to drug pre-
scribing and dispensing in older people could be highly
valuable as a routine screening tool. This is particularly
relevant currently, given the recent indication that ADEs
constitute the fifth leading cause of death in the United
States22 and other data showing that ADEs are a major
cause of hospitalization in older people2,23 as well as ex-
cess cost to the US taxpayer to a level of over $200 bil-
lion annually.24While there is a lack of research data from
prospective studies to show that routine application of
STOPP criteria results in significantly fewermajor ADEs,
recent data from a single-center randomized controlled
trial carried out by our research group25 show that older
hospitalized patients randomized to receive single time
point–structured application of STOPP criteria to their
medication lists had significantly improved medication
appropriateness on hospital discharge comparedwith pa-
tients receiving routine pharmaceutical care. Impor-
tantly, the improvement in medication appropriateness
was maintained at 6 months’ follow-up after discharge.
The STOPP criteria are not designed to capture all in-
stances of potentially inappropriate prescribing in older
people. Such a list would be too unwieldy to be of prac-
tical value in regular clinical practice. Rather, STOPP cri-
teria represent the more common avoidable instances of
inappropriate prescribing in older people in day-to-day
clinical practice. For this reason, instances of obvious
ADEs such as bleeding associated with coumarin use and
hypoglycemia associated with insulin use are not in-
cluded in STOPP criteria. STOPP criteria are designed
to be used in tandemwith START (ScreeningTool toAlert
doctors toRight Treatment) criteria.14 START criteria have
been validated14 in the same fashion as STOPP criteria
and represent the more common instances of inappro-
priate omission of potentially beneficial medication for
no valid clinical reasons. As with STOPP criteria, the
prevalence of potentially inappropriate omission of ben-
eficial drugs is substantial in older person populations
in primary care (22.7%)20 and hospital care (57.8%).25
The clinical benefit of using STOPP criteria as a tool
to prevent ADEs in older people remains unknown.How-
ever, given the data showing that routine application of
STOPP criteria significantly improvesmedication appro-
priateness comparedwith standard pharmaceutical care,24
there are reasonable grounds to propose that STOPP as
an intervention tool might also attenuate ADE inci-
dence in older people. However, another randomized con-
trolled trial is needed to address this research question.
A further important question is whether routine appli-
cation of STOPP and START criteria leads to significant
reductions in medication costs and health care utiliza-
tion costs.
Therewere some limitations to the present study.Non-
prescription OTC medications were not included in the
data collection, and there is a possibility that some ADEs
were related to OTC drugs not included in the analysis
of PIMs. However, it is unlikely that OTC drugs had a
significant influence on ADEs in the present study. Re-
cent unpublished data (2011) from our research group
on OTC drugs taken by older people with acute unse-
lected illness who are seen at the same hospital as de-
scribed in the present study show that the onlyOTCdrug
taken with any regularity is acetaminophen on an as-
occasion-requires basis for pain relief. Also, the strength
of the temporal relationship between the introduction of
PIMs and the onset of ADE symptoms was not determin-
able in the present data set. Similarly, the duration of treat-
ment with PIMs identified in this study was not re-
corded. Often, however, the onset of ADEs relating to
PIMs in older people is subtle and insidious, eg, toxic ef-
fects of digoxin in patients with chronic kidney disease
of gradual progression and falls relating to the use of neu-
roleptics. Instead, the study was firmly focused on the
presence or absence of PIMs, regardless of duration of
treatment.
Criteria for PIMs are notmeant to replace clinical judg-
ment; rather, they are designed to enhance clinical evalu-
ation of pharmacotherapy in older patients. Criteria for
PIMs in older people should be of benefit for prevention
of avoidable ADEs associated with prescription of such
PIMs. The present data indicate that STOPP criteria meet
this necessary requirement, whereas Beers criteria do not.
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INVITED COMMENTARY
Medication Safety
Are We There Yet?
D espite over 2 decades of research into medica-tion safety, preventable adverse drug events(ADEs) continue to be a problem of epidemic
proportions in the outpatient setting. A recent system-
atic review estimates that 18 ADEs and almost 7 prevent-
able ADEs occur per 100 outpatients annually.1 Reasons
for the relative lack of progress include the ever-
increasing use and types of medications at our disposal,
an incomplete understanding of the causes and predic-
tors of ADEs, and the lack of tools and techniques proven
effective in improving medication safety, particularly in
the outpatient setting. But by far the biggest problem is
the lack of implementation of those tools already shown
to be effective. For example, in Massachusetts in 2007,
only 35% of surveyed practices used an electronic health
record, and between 2005 and 2007 there had been no
significant increase in the availability or use of 9 of 10
See also page 1032
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